Performances of disk diffusion method for determining triazole susceptibility of Aspergillus species: Systematic review.
Antifungal susceptibility testing
Aspergillus
Disk diffusion method
Performance
Triazole
Journal
Journal de mycologie medicale
ISSN: 1773-0449
Titre abrégé: J Mycol Med
Pays: France
ID NLM: 9425651
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
21
12
2022
revised:
05
07
2023
accepted:
11
07
2023
medline:
13
11
2023
pubmed:
22
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
The therapeutic management of invasive aspergillosis should be guided by antifungal susceptibility testing (AFST). The disk diffusion (DD) method due to its simplicity and low cost could be an appropriate alternative to the reference methods (CLSI, EUCAST) which are not suitable for AFST in routine clinical microbiology laboratories, particularly in resource-constrained settings. This review summarizes the available data on the performance of the DD method in determining triazole susceptibility profile of Aspergillus species. The published articles on the performance of DD method for determining triazole susceptibility of Aspergillus spp. were systematically searched on major medical databases and Google Scholar. We identified 2725 articles of which 13 met the inclusion criteria. The overall average agreement value obtained between DD and CLSI broth microdilution (CLSI-BMD) methods for the itraconazole 10 µg disk (70.75%) was low especially when the medium used was not Mueller-Hinton (MH) agar. In contrast average agreement for the voriconazole 1 µg disk and the posaconazole 5 µg disk were > 94% regardless of media used. The correlation coefficient values between the DD and CLSI-BMD methods on MH agar were acceptable (≥ 0.71) for the itraconazole 10 µg disk and posaconazole 5 µg disk and good (≥ 0.80) for the voriconazole 1 and 10 µg disk. The reproducibility of the DD method regardless to the medium used was ≥ 82%. This systematic review shows that the disk diffusion method could be a real alternative for triazole antifungals susceptibility testing of Aspergillus spp.
Identifiants
pubmed: 37603962
pii: S1156-5233(23)00057-4
doi: 10.1016/j.mycmed.2023.101413
pii:
doi:
Substances chimiques
Voriconazole
JFU09I87TR
Itraconazole
304NUG5GF4
Agar
9002-18-0
Antifungal Agents
0
Triazoles
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101413Informations de copyright
Copyright © 2023 SFMM. Published by Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest. The funder of the study had no role in the design, data collection, data analysis and interpretation or writing of the report.